Thanks for response gtc |
Think if I recall right at the investor meet company the CFO said r&d and VAT credit this year was expected to be around 110k. They reduced r&d spend in that FY so won’t be as much as the previous one but still a nice top up. |
On 1st February last year, FAB announced a tax credit of £280k in respect of R&D for y/e 31 March 2023.
Can we expect a similar tax credit for year ending March 2024? |
Suspect the largish spread is the MMs protecting themselves from surprise "bunches" of sells or buys and having an unbalanced book as the weekend approaches. |
Been out all morning came back to see the price had dropped, logged on and then 2 x 100k buys knocked the price up again, over 300k shares bought in 10 minutes, got the last of mine into an ISA, now sit and wait for the year to develop. |
Looking at today's trades seems like everyone's given up on this week.
Just been rummaging ( back and sides) of sofa. Nothing to add unfortunately. |
I've still been adding all the way up to today...It just seems really good value at these levels... |
Suspect your FAB timing was ahead of mine.
Initially I accumulated up to 6.5p, but my left shoulder convinced the right to carry on and to take my FAB holding to an impudent(and imprudent!) share of my portfolio.
Never learn, heh? :-) |
Totally agree, I held 2.8m TERN shares several years ago when the price was down around 2p (I was deeply underwater) and in the space of a few months it went to over 50p, I sold 50k at 54.1p to repay a loan of £27k and then a speeding ticket 20 minutes later saw the price back in the thirties. Still it was a very good return once I had completely sold out, but it meant being tied up for years beforehand.
Hopefully I have timed the FAB entry well and have got better at identifying the recovery situations that will actually recover and thrive...(TERN is back down at sub 2p again) |
Yes trout
Price being affected in the current narrow range by relatively few trades.
My take is that apart from a few traders( in this case), the relatively small shares in issue (95m)are tightly held.
I've accumulated a mere 800k, which I suspect from reading this thread and LSE, is a quite modest holding compared to some with their ISAs and Sipps :-)
If I judge correctly many/most of these significant holders will not sell up when they've got to 25% paper profit.
When breakout occurs, there won't be much free stock available. |
Well back on topic with FAB, down from the UT close, then up and down again today, with what looks like roughly even buys and sells. Staying in a close range at the moment.
free stock charts from uk.advfn.com |
I just have this feeling that tomorrow will be a good day for FAB...
free stock charts from uk.advfn.com |
Next news will take this way past 10 |
Let's get through ( and stay through) 10p first. |
20p and some on NCI news |
thiopia
"Explains why he's buying FAB any opportunity he gets"
Can you please list all the occassions he has bought since his appointment?
There's a lot of trader talk again. Is it a coincidence the HVO is now silent and the share price has fallen back on lack of news? |
Was not aware of FAB CEO AbCam history.
Explains why he's buying FAB any opportunity he gets
AbCam employees who bought and held AbCam shares / Employee LTIP shares would have made big money |
Yep! Strong connections there, but we want a little more time, we want many multiples of current cap, we don't want a low ball offer, nothing less than three digits on sp |
Funny enough that FABs CEO used to work for Abcam…. |
 The most likely acquirer would be the type of Company that bought AbCam
i.e. Danaher
They bought AbCam for $5bn.
AbCam are rumoured to be a FAB client.
Would make sense the AbCam story was to have the most diverse catalogue of antibodies
WASHINGTON, Aug. 28, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher" or the "Company"), a global science and technology innovator, announced today that it has entered into a definitive agreement to acquire Abcam plc (NASDAQ: ABCM), a leading global supplier of protein consumables, pursuant to which Danaher will acquire all of the outstanding shares of Abcam for $24.00 per share in cash, or a total enterprise value of approximately $5.7 billion including assumed indebtedness and net of acquired cash.
Founded in 1998 and headquartered in Cambridge, UK, Abcam offers the scientific community highly validated antibodies, reagents, biomarkers and assays to address targets in biological pathways that are critical for advancing drug discovery, life sciences research, and diagnostics. Its technologies are used by approximately 750,000 researchers.
Abcam is expected to operate as a standalone operating company and brand within Danaher's Life Sciences segment, furthering Danaher's strategy to help map complex diseases and accelerate the drug discovery process. |
Hopefully the NCI news will come out before any offers for FAB itself. |
Register to chat with like-minded investors on our interactive forums.
Hot Features
Premium
